Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3',4'-dimethoxy-α-naphthoflavone.
We have characterized previously a class of aryl hydrocarbon receptor (AHR) ligand termed selective AHR modulators (SAhRMs). SAhRMs exhibit anti-inflammatory properties, including suppression of cytokine-mediated acute phase genes (e.g., Saa1), through dissociation of non-dioxin-response element (DRE) AHR activity from DRE-dependent xenobiotic gene expression. The partial AHR agonist α-naphthoflavone (αNF) mediates the suppressive, non-DRE dependent effects on SAA1 expression and partial DRE-mediated CYP1A1 induction. These observations suggest that αNF may be structurally modified to a derivative exhibiting only SAhRM activity. A screen of αNF derivatives identifies 3',4'-dimethoxy-αNF (DiMNF) as a candidate SAhRM. Competitive ligand binding validates DiMNF as an AHR ligand, and DRE-dependent reporter assays with quantitative mRNA analysis of AHR target genes reveal minimal agonist activity associated with AHR binding. Consistent with loss of agonist activity, DiMNF fails to promote AHR binding to DRE probes as determined through electromobility shift assay. Importantly, mRNA analysis indicates that DiMNF retains the suppressive capacity of αNF regarding cytokine-mediated SAA1 expression in Huh7 cells. Interestingly, predictive docking modeling suggests that DiMNF adopts a unique orientation within the AHR ligand binding pocket relative to αNF and may facilitate the rational design of additional SAhRMs. Microarray studies with a non-DRE binding but otherwise functional AHR mutant identified complement factor C3 as a potential SAhRM target. We confirmed this observation in Huh7 cells using 10 μM DiMNF, which significantly repressed C3 mRNA and protein. These data expand the classes of AHR ligands exerting DRE-independent anti-inflammatory SAhRM activity, suggesting SAhRMs may have application in the amelioration of inflammatory disorders.
Center for Molecular Toxicology and Carcinogenesis, Department of Veterinary Sciences, The Pennsylvania State University, University Park, PA 16802, USA.
Iain A
IA
Murray
Colin A
CA
Flaveny
Christopher R
CR
Chiaro
Arun K
AK
Sharma
Rachel S
RS
Tanos
Jennifer C
JC
Schroeder
Shantu G
SG
Amin
William H
WH
Bisson
Siva K
SK
Kolluri
Gary H
GH
Perdew
D000210:Acute-Phase Reaction / Q000378:metabolism; D001571:Benzoflavones / Q000494:pharmacology*; D002460:Cell Line; D003176:Complement C3 / Q000096:biosynthesis* / Q000235:genetics; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism; D008024:Ligands; D019920:Photoaffinity Labels / Q000378:metabolism; D011485:Protein Binding / Q000187:drug effects; D018336:Receptors, Aryl Hydrocarbon / Q000187:drug effects* / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000685:Serum Amyloid A Protein / Q000378:metabolism
C557505:3',4'-dimethoxy-alpha-naphthoflavone; D001571:Benzoflavones; D003176:Complement C3; D016207:Cytokines; D008024:Ligands; D019920:Photoaffinity Labels; D018336:Receptors, Aryl Hydrocarbon; C521404:SAA1 protein, human; D000685:Serum Amyloid A Protein; C011512:alpha-naphthoflavone